Aligos Therapeutics Aktie

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00pm ET.» Mehr auf globenewswire.com

SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately.» Mehr auf globenewswire.com

SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on May 13, 2025 (the “Grant Date”), in connection with the commencement of employment.» Mehr auf globenewswire.com